Meningococcal Vaccines Market Is Expected To Rise at a Stunning CAGR during the Forecast Period

The World Health Organization (WHO) is promoting the meningitis prevention strategy, introducing the vaccines in 26 countries in Africa suffering from meningitis and hoping to develop vaccines by 2016.Meningococcal vaccine is used to treat meningitis caused by N. meningitidis bacteria. Previously, there were no prior measures to prevent meningitis. After the infection was confirmed using antibiotics and nutritional supplements, the disease was cured. However, with the advent of the meningococcal vaccine, meningitis could be prevented.

The global vaccine market is estimated at $ 24 billion in 2013. The global increase in meningitis is a major driver of this market. As the awareness of diseases and vaccines increases, the meningococcal vaccine market also grows. Maintaining a cold chain for immunization increases immunization costs and is a major limiting factor in this market.

The Meningococcal clark vaccine market can be categorized as 4-valent, 2-valent, serum Group A, serum Group B and serum Group X depending on its type. Polysaccharides and combinations are two types of quadrivalent vaccines. A new vaccine called Baxsero, a combination vaccine, has been a huge success in preventing meningitis.

This market is categorized by region in North America, Europe, Asia Pacific and other countries (RoW). The North American market is the highest monetization area for this vaccine.

Download PDF Report Sample @ www.alliedmarketresearch.com/request-toc-and-sample/330

The major players in this market are Sanofi S.A., Novartis International, GlaxoSmithKline, Pfizer Inc., Serum Institute of India Ltd., JN-International Medical Corporation, Nuron Biotech, Baxter International and Biomed Pvt. Ltd. Novartis International with its new product is dominating the market. It has come up with a new vaccine named Baxsero, which has proved to be very beneficial in preventing meningitis. Pfizer Inc. is planning to target adolescent with their vaccine.

The report analyses global meningococcal vaccines market with the help of Porter’s five forces model. Porter’s model helps in analyzing the market players, new entrants in the market and the strategies adopted by them. In this market, the unavailability of substitutes result in high bargaining power of suppliers and low bargaining power of buyers. The meningococcal vaccine is a capital-intensive market; therefore, it is difficult for new entrants to enter the business. Market dynamics is analyzed for the benefit of the stakeholders.

Make an Enquiry before Buy @ www.alliedmarketresearch.com/purchase-enquiry/330

KEY BENEFITS

• Estimations are made by considering current market trends, and future potential investment for analysis period 2014-2020
• Benefits of meningococcal vaccines in prevention of meningitis are explained in the report
• In-depth analysis of market growth drivers, restraints and opportunities is done to assist the stakeholders in understanding the various factors affecting this market
• Macro environmental analysis of the market is done using Porter’s five forces model to analyze the various components of this industry.
• The market is analyzed based on its type and geography to help the stakeholders in understanding the market and its trends.

Access Full Summery @ www.alliedmarketresearch.com/meningococcal-vaccines-market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.